Optical Illusion: Why Genentech Is Winning the Fight Over Lucentis
This article was originally published in RPM Report
With Lucentis sales slumping, Genentech took the bold step of cutting off ophthalmologists from supply of Avastin, further angering providers already seething about the company's maneuvering around an NIH-funded comparative trial. The desperate move of a company painted into a corner? Hardly. Beneath the headlines, it looks like Genentech is going to win the fight to prevent Avastin from becoming standard care for AMD.
You may also be interested in...
The long awaited head-to-head trial of Avastin vs. Lucentis in macular degeneration has finally reported results. It pits a $1,500 a dose therapy against a $50, unapproved alternative that most providers think is just as good. We just had that debate over Makena. Recent comments by FDA’s top drug review official suggest there may be another connection.
The buzz at this year's annual meeting of the American Academy of Ophthalmology focused on two things: the presbyopia-correcting intraocular lens market, and the controversy surrounding the drugs Lucentis and Avastin for treating wet age-related macular degeneration.
The hot new buzzword with policymakers is comparative clinical effectiveness, and everyone has an idea on how to make it work. But major questions remain: what might a national effort look like? And will payors use it to restrict access to new drugs?